Cytokine release syndrome during sequential treatment with immune checkpoint inhibitors and kinase inhibitors for metastatic melanoma
F Dimitriou, AV Matter, J Mangana… - Journal of …, 2019 - journals.lww.com
Switching from immunotherapy to targeted therapy in metastasized melanoma can be
complicated by a cytokine release syndrome (CRS). CRS is a serious complication, which is
induced by high levels of circulating cytokines, associated with T-cell engagement and
proliferation, and results in a constellation of symptoms with variable organ involvement. We
report 2 patients with BRAF V600 mutant melanoma who were previously treated with anti-
PD-1±anti-LAG-3 antibodies and were switched to BRAF/MEK-inhibitors because of …
complicated by a cytokine release syndrome (CRS). CRS is a serious complication, which is
induced by high levels of circulating cytokines, associated with T-cell engagement and
proliferation, and results in a constellation of symptoms with variable organ involvement. We
report 2 patients with BRAF V600 mutant melanoma who were previously treated with anti-
PD-1±anti-LAG-3 antibodies and were switched to BRAF/MEK-inhibitors because of …
以上显示的是最相近的搜索结果。 查看全部搜索结果